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ABSTRACT 1 
Background: Vitamin B6 status is routinely measured as pyridoxal 5´-phosphate (PLP) 2 
in plasma. Low concentrations of PLP are associated with rheumatic, cardiovascular, and 3 
neoplastic diseases. We have previously shown that vitamin B6 status impacts the 4 
kynurenine pathway of tryptophan catabolism. 5 
Objective: To comprehensively evaluate the use of kynurenines as potential markers of 6 
functional vitamin B6 status across two large cohorts. 7 
Design: We measured circulating concentrations of the first 6 metabolites in the 8 
tryptophan catabolic pathway by LC-MS-MS in the community-based Hordaland Health 9 
Study (HUSK, n= 7017) and cardiovascular patient-based Western Norway Coronary 10 
Angiography Cohort (WECAC, n= 4161). Cross-sectional and longitudinal associations 11 
of plasma PLP with kynurenines was estimated using linear and non-linear regression-12 
based methods.  13 
Results: 3´-Hydroxykynurenine (HK), a substrate, and all four products formed directly 14 
by the PLP dependent enzymes kynurenine transaminase and kynureninase contributed to 15 
the explanation of circulating PLP in multivariable adjusted regression models. The 16 
construct HK:(kynurenic acid + xanthurenic acid + 3´-hydroxy anthranilic acid + 17 
anthranilic acid) termed HK-ratio (HKr) was related to plasma PLP with standardized 18 
regression coefficients (95% CI) of -0.47 (-0.49, -0.45) and -0.46 (-0.49, -0.43) in HUSK 19 
and WECAC, respectively. Across strata of cohort and sex, HKr was 1.3 - 2.7 fold more 20 
sensitive, but also 1.7 - 2.9 fold more specific to changes in PLP compared to a 21 
previously proposed marker HK:xanthurenic acid (HK:XA). Notably, the association was 22 
strongest at PLP concentrations < ~20 nmol/L, a recognized threshold for vitamin B6 23 
deficiency. Finally, PLP and HKr demonstrated highly sex-specific and corroborating 24 
associations with age. 25 
Conclusions: The results demonstrate that by combining five metabolites in the 26 
kynurenine pathway into a simple index, HKr, a sensitive and specific indicator of 27 
intracellular vitamin B6 status is obtained. The data also underscores the merit of 28 




Keywords: Vitamin B6, nutritional status, biomarker, inflammation, metabolic, 31 




The involvement of vitamin B6 in human metabolism includes the synthesis and 34 
interconversion of amino acids, neurotransmitters, nucleic acids, heme, and lipids. 35 
Vitamin B6 also plays an important role in energy homeostasis through glycogen 36 
degradation and gluconeogenesis. The versatility of pyridoxal 5`-phosphate (PLP), the 37 
active form of vitamin B6, is underscored by its use as a coenzyme in all the major 38 
enzyme classes except for ligases (1). Both vitamin B6 intake and plasma indicators of 39 
vitamin B6 status have been associated with clinical conditions including, but not limited 40 
to, rheumatoid, cardiovascular and neoplastic diseases as well as mortality in cross-41 
sectional and prospective studies (2-5).  42 
 One of the earliest described indicators of low vitamin B6 status was the increased 43 
excretion of the tryptophan catabolite xanthurenic acid (XA) in urine after a tryptophan 44 
load (6). Subsequently, a number of metabolites along the kynurenine pathway of 45 
tryptophan catabolism were found to be increased in the urine of vitamin B-6 deficient 46 
humans, including the ratio of 3´ hydroxykynurenine:3`hydroxyanthranilic acid 47 
(HK:HAA) (7,8). An overview of tryptophan metabolism and its two PLP-dependent 48 
steps is shown in Figure 1. Methods and protocols for quantification of these and other 49 
functional markers of vitamin B6 status are often cumbersome, however, and have 50 
largely been abandoned after sensitive and precise measurements of plasma PLP became 51 
available (9,10). Although plasma PLP is accepted as an indicator of nutritional vitamin 52 
B6 status, PLP has been found to be redistributed from plasma to tissues e.g. erythrocytes 53 
and liver, during inflammation, which may complicate the interpretation of plasma PLP 54 
in observational studies (3,11).   55 
 A decade ago we expanded an assay for the quantification of the B6 vitamers 56 
(PLP, pyridoxal (PL), and 4´-pyridoxic acid (PA)) in serum/plasma to also include 57 
tryptophan and the first 6 metabolites of the tryptophan degradation pathway. In a cohort 58 
of suspected coronary artery disease (CAD) patients we noted that HK was markedly 59 
increased at plasma PLP concentrations below 20 nmol/L, a cut-off suggested to indicate 60 
vitamin B6 deficiency (12). In a follow-up study we evaluated substrate:product ratios of 61 
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the two PLP-dependent enzymes kynurenine aminotransferase (KAT) and kynureninase 62 
(KYNU) and found that HK:xanthurenic acid (HK:XA) exhibited both increased 63 
sensitivity and specificity for PLP compared to HK alone (13). Subsequently, this, and 64 
other kynurenine-ratios, have been associated with increased risk of cancers of the lung 65 
(14), and colon (15), mortality in renal transplant recipients (16), and with treatment 66 
efficacy in rheumatoid patients (J Nut, in press). 67 
 Previously, we evaluated kynurenines in a cohort of confirmed and suspected 68 
coronary artery disease (CAD) patients (13). The objective of the present study was to 69 
perform an in-depth exploration of the concept of kynurenines as metabolic markers of 70 
vitamin B6 status and to extend and diversify the population base to include more CAD 71 
patients as well as participants from a large community-based cohort, the Hordaland 72 
Health Study (HUSK). 73 
 74 
SUBJECTS AND METHODS 75 
Study populations 76 
The Hordaland Health Study (HUSK) is a community-based longitudinal observational 77 
study whose baseline measurements were conducted during 1997-1999 78 
(http://husk.b.uib.no). Details of the study design and methodology have been described 79 
elsewhere (17,18). The HUSK cohort, as used here, encompasses 7050 men and women 80 
who were born during 1925-1927 or 1950-1951 and living in or adjacent to the city of 81 
Bergen, Norway. After exclusion of 126 participants with missing data on PLP and 82 
kynurenines, cross-sectional data for 6924 participants (3062 men and 3862 women) 83 
were included in the present analyses. The Western Norway Coronary Angiography 84 
Cohort (WECAC) consists of 4164 patients that underwent elective coronary 85 
angiography due to suspected stable angina pectoris between 2000 and 2004 (19). About 86 
2/3 of these patients participated in the Western Norway B-Vitamin intervention Trial 87 
(WENBIT), which evaluated the lowering of plasma homocysteine by oral B-vitamin 88 
treatment to prevent future cardiovascular events. The four treatment groups consisted of 89 
1) 0.8 mg folic acid, 0.4 mg cyanocobalamin and 40 mg pyridoxin, 2) 0.8 mg folic acid, 90 
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0.4 mg cyanocobalamin, 3) 40 mg pyridoxin,and 4) placebo in a 2x2 factorial design. 91 
WENBIT is described in detail elsewhere (20). After exclusion of 45 participants with 92 
missing data on PLP and kynurenines, cross-sectional data for 4119 participants (2960 93 
men and 1159 women) were included in the present analyses. In addition, for the 94 
WENBIT study participants, we used data also from the first study visit to evaluate the 95 
association of changes in PLP with changes in kynurenines across 28 days. Complete 96 
data for 2508 participants were available for this analysis. Participant flow charts for 97 
HUSK and WECAC are available as Supplemental Figure 1 and 2, respectively. 98 
 99 
Sociodemographic and anthropometric variables 100 
Sociodemographic and anthropometric data were obtained by self-administered 101 
questionnaires (HUSK), or interview (WECAC). Smoking status was based on self-102 
reported smoking habits corrected by plasma cotinine, i.e. patients initially classified as 103 
non-smokers, but with plasma cotinine ≥ 85 nmol/L (21) were re-classified as smokers. 104 
Height and weight were measured using standardized protocols, and body mass index 105 
(BMI) was calculated by dividing weight by height squared (kg/m2).  106 
 107 
Laboratory analyses  108 
Non-fasting blood samples were collected into tubes containing EDTA, kept on ice 109 
before centrifugation (within 3 hr), and stored at -80°C before analysis. Plasma 110 
concentrations of PLP, tryptophan, kynurenines, neopterin, cotinine, and creatinine were 111 
quantified by liquid chromatography/tandem mass spectrometry at Bevital, Bergen, 112 
Norway (www.bevital.no) (22,23). C-reactive protein (CRP) was measured in serum 113 
using an ultrasensitive immunoassay, Behring nephelometer II system N Latex CRP 114 
mono (Behring Diagnostics, Marburg, Germany) (WECAC) or in plasma with an 115 
immuno-MALDI based assay (HUSK) (24). Further details concerning handling and 116 
storage of blood samples before analysis (WECAC) have been described previously 117 
(19,25,26).  118 
 119 
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Statistical methods 120 
All continuous variables were log-transformed before inclusion in parametric regression 121 
models to satisfy the criterion of normality of residuals in linear regression analysis. 122 
Differences by gender were evaluated by Mann-Whitney U test for continuous, and 123 
Fisher´s exact test for categorical data. The correlation between kynurenines were 124 
estimated by Pearson´s r adjusted for age and sex. Linear- and non-linear associations 125 
between vitamin B6 markers and PLP were evaluated by multivariable linear regression, 126 
generalized additive models (GAM), and segmented regression. Subcohorts were based 127 
on dichotomous variables, or, if continuous, above vs. below the median. Data was 128 
divided into low and high inflammation according to the median of the product of  CRP, 129 
neopterin, and the kynurenine:tryptophan ratio (KTR) . Predictors of vitamin B6 markers 130 
were evaluated using "relative importance regression". This method combines multiple 131 
linear regression with the algorithm "lmg" as described (27). Briefly, the algorithm 132 
evaluates all possible models and all sequences for addition to a regression model that 133 
can be applied to a given set of predictors (regressors). The impact of each regressor is 134 
then averaged over these models using the percentage explained variance as metric. The 135 
predictors included age, smoking (current/no current), BMI, creatinine, CRP, neopterin, 136 
KTR, and PLP, and analyses were performed separately for men and women. From the 137 
output of these analyses we calculated performance indices using the following 138 
definitions: sensitivity, the amount of variation in the outcome explained by PLP; 139 
specificity, the ratio of this number to the total explained variation; and performance as 140 
sensitivity * specificity. Notably, these terms should not be confused by similar terms 141 
used in receiver operating curve (ROC) analysis. We used R for Macintosh version 3.5.2  142 
for all statistical calculations, with R-packages "mgcv" for GAM, "segmented" for 143 
segmented regression, and "relaimpo" for the multiple linear regression-based assessment 144 
of relative importance of predictors. 145 
 146 
RESULTS 147 
Characteristics of the study populations 148 
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The HUSK cohort consisted of two distinct age groups: 46-47 years (52.8%) and 70-72 149 
years, with ~56% women in each age group. In WECAC, the median (IQR) age was 61 150 
(14) years for men, and 64 (15) years for women, with 28.1% women. The concentrations 151 
of tryptophan and the kynurenines were similar in HUSK and WECAC (Table 1). In both 152 
cohorts, the concentrations of Trp, Kyn, KA, XA and HAA were higher in men than 153 
women. PLP concentrations were similar across genders, but both HK:XA and the ratio 154 
HKr = HK:(KA+XA+HAA+AA) were higher in women (Table 1). In WECAC, 2125 155 
patients (52%) had previously established cardiovascular disease, and 3082 (75%) had 1 156 
or more stenotic vessels based on coronary angiography.     157 
 158 
Initial exploration of the relation between PLP and kynurenines 159 
We modeled PLP by linear regression and stepwise selection using the kynurenines 160 
downstream of Kyn as candidate predictors while keeping age and sex as fixed 161 
covariates. In both HUSK and WECAC, HK was selected as the first (and only negative) 162 
predictor of PLP followed by all four of XA, KA, HAA, and AA (postitive predictors). In 163 
unadjusted analyses, we confirmed that the proportions of KA, XA, HAA, and AA all 164 
increased while HK decreased across quartiles of PLP. The correlations (Pearson´s r 165 
adjusted for age and sex) of KA, XA, HAA, and AA with their sum were 0.85, 0.76, 0.49, 166 
and 0.79, respectively in HUSK, and 0.88, 0.80, 0.52, and 0.71 in WECAC. Inspired by 167 
these results, the ratio HKr = HK:(KA+XA+AA+HAA) was constructed as a candidate 168 
marker of vitamin B6 status. We also included ratios aimed at specifically characterizing 169 
kynurenine aminotranferase (KAT) denoted HKKAT = HK/(KA+XA), and kynureninase 170 
(KYNU): HKKYNU = HK/(AA+HAA). In the following we will refer to kynurenines, 171 
either singly or in combination as (potential) functional vitamin B6 markers.  172 
 173 
Linear associations between PLP and selected vitamin B6 markers 174 
We evaluated the linear association of PLP with vitamin B6 markers by multiple linear 175 
regression adjusted for age and sex (Table 2). Notably, kynurenine combinations (ratios) 176 
were more strongly associated with PLP than individual metabolites, and HKr 177 
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demonstrated the strongest association with PLP in both cohorts. The associations of PLP 178 
with Kyn and the ratios Kyn:KA and Kyn:AA were all weak (standardized betas  > -179 
0.14). When evaluated in strata based on sex, age, vitamin supplement use, and 180 
inflammation (both cohorts) and according to established CVD at baseline and ≥ 1 181 
stenotic vessel (WECAC), HKr was consistently the best marker in terms of strength of 182 
association with PLP.  183 
 184 
Determinants of vitamin B6 markers  185 
We evaluated the association of selected vitamin B6 markers with age, BMI, current 186 
smoking, kidney function (creatinine), inflammation, as represented by the three variables 187 
CRP, neopterin, and KTR, and PLP using relative importance regression stratified by sex. 188 
Results for the markers HK, HK:XA and HKr in WECAC are shown in Figure 2 and 189 
relative performances of the markers by cohort and sex are summarized in Table 3. As 190 
demonstrated in Figure 2 and Table 3, both the sensitivity and specificity for PLP 191 
increased in the direction of more complex ratios, and, again, except for specificity in 192 
WECAC females, HKr was the best scoring marker in all strata (Table 3). In addition to 193 
the markers included in Table 3 we also evaluated a construct where the four downstream 194 
kynurenines were standardized before summation, and another construct where we used 195 
the product instead of the sum of the four downstream kynurenines. Compared to HKr, 196 
the performance of these alternative markers were considerable poorer by the criteria 197 
used in Table 3. 198 
 199 
The association of vitamin B6 markers with PLP by generalized additive models 200 
regression (GAM) 201 
Figure 3 shows the association of HK, HK:XA and HKr with PLP in HUSK by GAM. 202 
Corresponding, and very similar, results were found in WECAC (Supplemental Figure 203 
3). Common to all markers was a markedly stronger association at low compared to 204 
normal and high PLP concentrations. Using segmented regression, we identified a 205 
breakpoint at 19.4 (18.1, 20.7) nmol/L PLP for the HKr-PLP association in HUSK and a 206 
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similar breakpoint at 19.1 (17.4, 20.9) nmol/L in WECAC (Supplemental Figure 3). 207 
Close examination of the GAM-curves suggested a transitional segment of intermediate 208 
sensitivity to PLP in the interval of approximately 20 - 40 nmol/L in both cohorts, but we 209 
were unable to obtain reproducible breakpoints for a possible intermediate segment by 210 
segmented regression. 211 
 212 
Longitudinal associations 213 
For WECAC patients that participated in the WENBIT trial we had data on PLP and 214 
vitamin B6 markers at baseline, and the 28 days study visit. Moreover, one arm of the 215 
2x2 factorial RCT design included a daily oral dose of 40 mg pyridoxine. Thus, we were 216 
able to assess the change in vitamin B6 markers according to both natural variation in 217 
PLP (across 28 days) and, according to pyridoxine treatment. Figure 4 shows GAM-plots 218 
of the change in HKr vs. change in PLP in the non-treated and pyridoxine-treated groups. 219 
Standardized linear regression coefficients for the associations in the non-treated, and 220 
treated groups were -0.34 and -0.48, respectively. Corresponding associations were -0.33 221 
and -0.44 for HK:XA and -0.11 and -0.33 for HK. The mean overall reductions in HKr, 222 
HK:XA, and HK in the vitamin B6 treated groups were 39, 31, and 34%, respectively. 223 
The above findings were not altered by adjustment for the folic acid + cobalamin 224 
treatment arm 225 
 226 
PLP and HKr by age and sex. 227 
We found a steady and, apparently, slightly accelerating decline in vitamin B6 status with 228 
age among WECAC men as indicated by both PLP and HKr. For women, B6-status 229 
appeared to improve until age 55 and then declined at an increasing rate at age > 55 230 
years. Again, the PLP and HKr findings closely mimicked each other (Figure 5). 231 
 232 
DISCUSSION 233 
Principal findings 234 
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In the present study we evaluated both circulating concentrations and ratios of 235 
kynurenines as potential functional markers of vitamin B6 status in one community-based 236 
and one clinical cohort. Among the panel of candidate markers, the best performance 237 
characteristics were found for the ratio HK:(KA+XA+HAA+AA), abbreviated HKr. 238 
Compared with kynurenine-based markers proposed earlier (13) and additional markers 239 
included in this study, HKr demonstrated stronger associations with PLP, both in cross-240 
sectional and longitudinal analyses, and also considerably increased specificity for PLP. 241 
The findings were consistent across cohorts and subgroups and featured a two-segmented 242 
dose-response curve with a cut-off close to 20 nmol/L, a threshold suggested to indicate 243 
B6 deficiency (28,29). 244 
 245 
 Possible mechanisms 246 
Previously, we reported the characteristics of the two substrate product ratios HK:XA, 247 
and HK:HAA and the closely related HK:KA and HK:AA within the WENBIT cohort 248 
(13). The rationale for using substrate:product pairs was discussed previously (13), and a 249 
more theoretical basis may be found in metabolic control theory (30). Briefly, by taking 250 
ratios, the influence of confounders common to the nominator and denominator would 251 
tend to be attenuated, whereas information related to the enzyme dependency, in this case 252 
the intracellular availability of PLP, would be amplified. Interestingly, the best overall 253 
marker in the current study was a construct made of HK in the nominator and the sum of 254 
all four kynurenines downstream of the two PLP-dependent enzymes KAT and KYNU in 255 
the denominator. To gain a better understanding we also evaluated ratios limited to KAT, 256 
i.e. HK:(KA+XA), and KYNU, i.e. HK:(AA+HAA) and observed characteristics 257 
intermediate to those of the corresponding simple ratio (e.g. HK:HAA) and the full HKr.  258 
Closer examination of the results in Table 3 showed that a main benefit of using sums of 259 
downstream kynurenines, e.g. KA + XA, in the denominator was an increase in 260 
specificity. Further, the main benefit of using the full HKr over HKKAT and HKKYNU was 261 
greater consistency in performance across cohort and gender. The ratios Kyn:KA and 262 
Kyn:AA were only weakly related to PLP. The likely reason is that Kyn is readily 263 
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converted to HK by FAD-dependent kynurenine mono-oxygenase (KMO) and thus does 264 
not accumulate as PLP becomes limiting. Riboflavin status has been shown to affect the 265 
activity of KMO (31), but did not materially affect the relation between PLP and B6 266 
markers in the present study. The mean concentrations of KA, XA, HAA and AA differed 267 
by up to 3-fold, but correlation analysis showed that variation in their sum (as used in the 268 
denominator of HKr) was not overly dominated by any one of the individual kynurenines. 269 
Notably, a construct using the product of downstream kynurenines in the denominator 270 
was inferior to HKr. Similarly, replacing the downstream kynurenines with the sum or the 271 
product of their standardized equivalents did not improve overall performance 272 
characteristics. A likely reason for the utility of the plain sum of KA, XA, AA, and HAA 273 
in HKr may be that they all share the same source, kynurenine.  274 
 275 
Reproducibility of findings 276 
In our previous report on substrate product ratios we concluded that HK:XA had slightly 277 
better characteristics than HK:HAA as a potential functional marker of vitamin B6 status 278 
(13). Using a more stringent (quantitative) analysis based on relative importance 279 
regression we confirmed this finding in the larger WECAC cohort. In HUSK, however, 280 
the performance of HK:XA was clearly inferior to that of HK:HAA. The reason for this 281 
discrepancy is not clear. The performance of HKr was, by comparison, consistent. 282 
Conceivably, this could be explained by HKr capturing information from both enzymes, 283 
which might have a stabilizing effect on performance across cohorts and subgroups.  284 
 285 
HKr and PLP-based cutpoints for overt, and marginal vitamin B6 deficiency 286 
The HKr index demonstrated a markedly increased sensitivity to changes in PLP 287 
concentration at PLP concentrations below ~ 19 nmol/L in both the HUSK and WECAC 288 
cohorts. This result may be regarded as supportive for the concept of HKr as a functional 289 
marker of vitamin B6 status, but, conversely, it can also be viewed as novel and direct 290 
metabolic support for a cutpoint of 20 nmol/L for vitamin B6 deficiency. Several 291 
investigators have studied a related concept of marginal deficiency defined as PLP 292 
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concentrations in the interval 20 - 30 nmol/L (32). In the GAM analyses there was some 293 
support for a segment in the interval 20 - 40 nmol/L PLP where the association with HKr 294 
was intermediate. The HKr decreased further beyond 40 nmol/L PLP, thus, it would be 295 
hard to use the present data to argue for a specific threshold for sub-optimal vitamin B6 296 
status. Although, the data only offers limited support, it certainly does not conflict with a 297 
concept of marginal vitamin B6 deficiency in an interval stretching from 20 to 30 nmol/L 298 
PLP or even above. 299 
 300 
HKr and differences according to age and sex 301 
HKr was markedly higher in women than in men in both HUSK and WECAC (13, and 302 
18% higher respectively, age-adjusted), while corresponding values for PLP were 4% 303 
higher and 5% lower. Notably, both KAT and KYNU has been found to be inhibited by 304 
estrogen (33) which could explain the lower concentrations of KA, XA, and HAA, and 305 
therefore higher HKr, in women. Declining estrogen levels (34) could also, potentially, 306 
explain the downward trend in HKr until about 55 years. Notably, however, high 307 
estrogen, e.g. from oral contraceptives, or around the time of ovulation, is associated with 308 
low PLP (29). Thus, the similarity of the PLP- and HKr-age assocation curves suggests 309 
that the age-related differences in HKr, is mediated through changes in PLP rather than 310 
resulting from direct effects of estrogen on KAT and KYNU. In men, and in women older 311 
than 55 years, vitamin B6 status decreased according to both indicators. The rate of 312 
decline corresponded well with a previously published value of 4 nmol/decade (35) and 313 
with other reports (36). Possible explanations could include increased inflammation 314 
and/or age-related differences in nutrition (3,36). 315 
 316 
Strength and limitations 317 
The main strengths of the study included the use of an established mass-spectrometry 318 
based assay that quantifies tryptophan, all the kynurenines, and PLP in a single run. We 319 
were able to use data from two large cohorts with notable differences in characteristics to 320 
assess reproducibility and consistency. Furthermore, data from WENBIT participants 321 
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allowed us to evaluate both longitudinal aspects and responses to intervention with 322 
vitamin B6 (pyridoxin). The main limitation was the lack of a third, independent, marker 323 
of vitamin B6 status. We could only evaluate the kynurenine-based markers against 324 
plasma PLP. 325 
  326 
Conclusions  327 
In this paper we describe an in-depth exploration of circulating kynurenines as functional 328 
markers of vitamin B6 status. The marker with best performance and overall 329 
characteristics was a construct, HKr, which included 5 of the 6 metabolites immediately 330 
up- and downstream of the two PLP-dependent enzymes in the kynurenine pathway. The 331 
results for HKr were reproducible across cohorts and subgroups, and its appropriateness 332 
was further corroborated by highly sex-specific age-associations indicated by both PLP 333 
and HKr.  334 
 Many of the kynurenines measured in this study have neuromodulatory and/or 335 
immunological effects and have been linked to various pathologies including psychiatric 336 
disorders, cognitive decline, cancer, and cardiovascular disease (37,38). Since low 337 
vitamin B6 status has been found for many of the same conditions (10, 11), it should be 338 
of great value to jointly investigate kynurenines and vitamin B6 status in future studies of 339 
clinical outcomes. 340 
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Table 1. Characteristics of the study population1 
  HUSK    WECAC  
 Men Women p2  Men Women p2 
        
n (%) 3062 (44.2) 3862 (55.8)   2960 (72.0) 1159 (28.1)  
Age  46-47y, n (%) 1623 (44.4) 2033 (55.6)      
Age  70-72y, n (%) 1439 (44.0) 1829 (56.0)      
Age (y)     61 (15) 64 (15) < 0.001 
Current smoker, n (%) 906 (29.6) 1044 (27.0) 0.02  1003 (33.9) 305 (26.3) < 0.001 
BMI (kg/m2) 25.8 (4.0) 24.9 (5.5) < 0.001  26.4 (4.3) 26.1 (6.1) 0.009 
Creatinine (mmol/L) 88.5 (15.5) 73.7 (12.7) < 0.001  77.4 (18.1) 64.8 (16.3) < 0.001 
PLP (nmol/L) 50.5 (35.8) 49.8 (44.4) 0.80  42.0 (29.6) 39.7 (32.2) 0.10 
Trp (mmol/L) 70.5 (18.0) 64.3 (17.5) < 0.001  71.4 (18.7) 66.5 (19.1) < 0.001 
Kyn (mmol/L) 1.59 (0.56) 1.45 (0.56) < 0.001  1.70 (0.61) 1.63 (0.66) 0.005 
HK (nmol/L) 31.9 (14.4) 32.5 (14.8) 0.05  30.1 (15.2) 32.8 (17.6) < 0.001 
KA (nmol/L) 48.9 (23.2) 42.5 (21.3) < 0.001  50.1 (26.1) 43.0 (21.7) < 0.001 
XA (nmol/L) 16.9 (10.5) 14.7 (9.4) < 0.001  15.1 (9.9) 12.7 (9.4) < 0.001 
AA (nmol/L) 14.4 (6.7) 14.0 (6.3) 0.001  14.3 (6.9) 14.5 (7.0) 0.64 
HAA (nmol/L) 35.2 (17.3) 31.9 (15.7) < 0.001  35.9 (19.9) 30.7 (16.0) < 0.001 
HK:XA (no units) 1.88 (1.04) 2.19 (1.45) < 0.001  1.99 (1.08) 2.48 (1.78) < 0.001 
HKr x100 (no units) 26.9 (9.6) 30.1 (12.1) < 0.001  25.5 (10.1) 31.0 (14.4) < 0.001 
CRP (mg/L) 1.62 (2.8) 1.54 (3.0) 0.03  1.77 (2.70) 1.80 (3.1) 0.07 
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KTR (nmol/µmol) 22.6 (9.2) 22.5 (9.7) 0.52  23.5 (8.9) 24.8 (10.2) < 0.001 
Neopterin (nmol/L) 7.5 (2.9) 7.8 (3.0) < 0.001  7.9 (3.4) 8.9 (4.3) < 0.001 
1Numbers are medians (IQR) if not otherwise indicated.  
2 Mann Whitney U test or Fisher´s exact test for difference between men and women 
AA, anthranilic acid; CRP, C-reactive protein; HAA, 3-OH anthranilic acid; HK, 3-OH kynurenine; HKr, HK:(KA+XA+AA+HAA); KA, kynurenic acid; Kyn, 
kynurenine; KTR, kynurenine:tryptophan (ratio); PLP, pyridoxal 5´-phosphate; Trp, tryptophan; XA, xanthurenic acid 
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Table 2. Linear associations between vitamin B6 markers and PLP1 
 HUSK  WECAC 
Single kynurenines    
   HK -26 (-29, -24)  -25 (-28, -22) 
   KA 13 (10, 15)  13 (10, 16) 
   XA 13 (10, 15)  17 (14, 20) 
   AA 7 (4, 9)  10 (7, 13 ) 
   HAA 17 (15, 20)  12 (9, 15) 
Ratios flanking KAT    
   HK:KA -38 (-41, -36)  -37 (-40, -35) 
   HK:XA -33 (-35, -30)  -41 (-44, -38) 
   HKKAT = HK:(KA+XA) -41 (-43, -39)  -41 (-44, -38) 
Ratios flanking KYNU    
   HK:AA -28 (-30, -26)  -29 (-32, -27) 
   HK:HAA -43 (-45, -41)  -38 (-41, -35) 
   HKKYNU = HK:(AA+HAA) -43 (-46, -41)  -40 (-43, -38) 
Ratio flanking both enzymes    
   HKr = HK:(KA+XA+AA+HAA) -47 (-49, -45)  -46 (-49, -43) 
1Numbers are standardized regression coefficients x 100 (95% CI) adjusted for 
age and sex. All associations were significant at P < 0.0001. AA, anthranilic  
acid; HAA, 3-OH anthranilic acid; HK, 3-OH kynurenine; KA, kynurenic acid;  
KAT, kynurenine transaminase; KYNU; kynureninase; XA, xanthurenic acid. 
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Table 3. Performance characteristics of selected markers of vitamin B6 status1 
  HUSK    WECAC  











Men        
   HK 2.4 7.4 0.2  2.3 5.7 0.1 
   HK:XA 6.5 22.4 1.5  8.9 36.5 3.3 
   HKKAT = HK:(KA+XA) 9.3 54.9 5.1  9.0 59.2 5.3 
   HK:HAA 12.1 45.3 5.5  8.2 26.3 2.1 
   HKKYNU = HK:(AA+HAA) 11.5 52.3 6.0  9.2 33.1 3.0 
   HKr = HK:(KA+XA+AA+HAA) 12.8 60.8 7.8  11.6 61.7 7.2 
        
Women        
   HK 7.3 24.2 1.8  4.9 11.5 0.6 
   HK:XA  8.0 25.5 2.0  12.1 34.9 4.2 
   HKKAT = HK:(KA+XA) 16.2 67.6 10.9  16.5 62.2 10.3 
   HK:HAA 18.4 57.5 10.6  11.7 29.9 3.5 
   HKKYNU = HK:(AA+HAA) 19.3 66.6 12.9  14.4 38.5 5.5 
   HKr = HK:(KA+XA+AA+HAA) 21.9 73.1 16.0  19.0 58.6 11.1 
1Performance characteristics were calculated based on multiple linear regression and the "lmg" algorithm as implemented in the "relaimpo"  
package in R, as further described in "Statistical methods". (The main output from the method is illustrated in Figure 2.) 
AA, anthranilic acid; HAA, 3-OH anthranilic acid; HK, 3-OH kynurenine; KA, kynurenic acid; XA, xanthurenic acid.
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LEGENDS TO FIGURES 
 
Figure 1. Tryptophan metabolism through the kynurenine pathway  
Enzymes and cofactors are shown. IDO is activated by inflammatory stimuli including 
INF-γ, which also stimulates macrophages to produce neopterin. The immediate product 
of TDO and IDO, formylkynurenine, is not shown. AA, anthranilic acid; HAA, 3-OH 
anthranilic acid; HK, 3-OH kynurenine; INF-γ, interferon-γ; KA, kynurenic acid; Kyn, 
kynurenine; KAT, kynurenine aminotransferase; KMO, kynurenine 3-monooxygenase; 
KYNU, kynureninase; IDO, indoleamine 2,3 dioxygenase; PLP, pyridoxal 5´-phosphate; 
TDO, tryptophan 2,3 dioxygenase; Trp, tryptophan; XA, xanthurenic acid. 
 
Figure 2. Relative importance of predictors of HK, HK:XA, and HKr in WECAC 
The amount of variation in HK, HK:XA and HKr attributable to PLP and relevant 
confounders is shown. Calculations were based on multiple linear regression and the  
"relaimpo" package in R, with R2 as the metric for explained variation. Negative, and 
positive associations are depicted with light grey, and black color, respectively. CRP, C-
reactive protein; KTR, kynurenine:tryptophan ratio; PLP, pyridoxal 5´-phosphate. 
 
Figure 3. Association of HK, HK:XA and HKr with PLP in HUSK by GAM  
Grey shaded areas indicate the 95% CI. A density plot for the distribution of PLP is 
included in each panel with white lines indicating the 5th, 20th, 50th, 80th, and 95th 
percentile. The horizontal dotted line marks the adjusted mean concentration of the 
vitamin B6 marker. For the HKr-association, two segments, calculated by segmented 
regression, is overlaid (red color) on the GAM-curve, and a significant breakpoint at 19.4 
(18.1, 20.7) nmol/L is indicated by the vertical dotted line. GAM, generalized additive 
models. 
 
Figure 4. Change in HKr versus change in PLP by GAM  
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Change is defined as the concentration of the vitamin B6 marker 28 days into the study 
(WENBIT) divided by the concentration at baseline. A: non-treated groups (n=1130). B: 
groups treated with a daily oral dose of 40 mg pyridoxine (n=1138). Grey shaded areas 
denote the 95% CI. The distribution of ΔPLP is shown at the bottom of each panel with 
white lines indicating the 5th, 20th, 50th, 80th, and 95th percentile. Horizontal and 
vertical dotted lines indicate where no change from baseline to day 28 is found (ratio = 
1). 
 
Figure 5. The association of HKr with age in WECAC by GAM 
Grey shaded areas denote the 95% CI. The age-distribution is shown at the bottom of 
each panel with white lines indicating the 5th, 20th, 50th, 80th, and 95th percentile. The 
horizontal dotted line in each panel indicate the adjusted mean concentration of the 
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